You are offline. Saved alerts are still available. Live updates resume when you reconnect.
Reading a stock page
- The tabs show the price chart, results, shareholding, events and news for this one company.
- The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
- Every figure names its source. "Official" means it came from NSE or BSE filings.
- Use the star to watch the stock, or Add to portfolio to record a trade.
🎯 Buy It or Not? — Complete Intraday to Long-Term Decision Report for VALIANTLAB (NSE)
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
47
ISA Signal Score: Neutral
Trend60
Momentum33
52-week range49
Volume24
Risk57
Fundamentals48
Working for it
- Price is above its 200-day average (long-term uptrend)
- 50-day average is above the 200-day average
- 50-day average is rising
- Revenue grew 78% year on year
Working against it
- Price is below its 20-day average
- Price is below its 50-day average
- RSI 23: weak (oversold, but not turning yet)
- More volume on down days than up days (distribution)
- Low ROE (0%)
Red flags
- Thinly traded: average daily turnover is low, so entering or exiting can be hard
At a glance
QualityNot knownNeeds the yearly results. They load from NSE on their own for NSE stocks.
GrowthFastSales 14.2% a year over 2 years
ValuationNo earningsP/E cannot be worked out while the company makes a loss.
MomentumStrongAbove its 200-day average, beat NIFTY 50 by 24.8 points
RiskHighSwings 53% a year, fell up to 34% from a peak, beta 0.64
Smart Investor Tips: VALIANTLAB
Caution Warranted (Trend or Balance-Sheet Headwinds)Actionable Insights & Positives
- Pullback within a long-term uptrend: holding above the 200-day average (Rs 81.86) while digesting gains below the 50-day average (Rs 120.41).
- RSI is oversold at 23 (< 30). Watch for a bullish reversal candle (hammer or engulfing) with volume confirmation.
- Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.
Risk Checks & Things to Verify
- Reported a net loss in FY26. Turnaround stories carry higher execution risk.
NSE MCP Live & 5-Year Check No API Key
Algorithmic Momentum Prediction & Optimal Entry PriceWEAK / REDUCE ON BOUNCES (Score 26/100)
Weak trend, debt overhang, or distribution. Avoid fresh buying until price reclaims 50-DMA (Rs 120.41). If already held, protect capital if it breaks below Rs 77.48 or trim near resistance Rs 130.88.
| Optimal Support area | Tranche 1 (50%) | Tranche 2 (50%) | Risk level / Review | Level 1 (Swing) | Level 2 (Breakout) | Risk : Reward |
|---|---|---|---|---|---|---|
| Rs 91.53 – Rs 94.91 Ideal ~Rs 93.22 |
Rs 94.91 | Rs 91.53 | Rs 77.48 ATR 2.5% |
Rs 130.88 | Rs 141.38 | 1 : 2.4 RSI 0 · Vol 0.60x |
Live Candlestick & TradingView Chart (VALIANTLAB)
MARKET CLOSED - EOD SNAPSHOTKey figures
P/E-loss making
P/B-price / book value
EPSRs -0.55earnings per share
Dividend yield-from saved dividend events
Debt to equity-borrowings / equity
Sales growth14.2%a year over 2 years
Profit growth-yearly, needs 2+ years
Operating margin2.7%net margin -1.4%
Company Debt, Borrowings & Cash Flow Health
Total Debt / Loans
-
Long + short-term loans
Cash & Bank Balances
-
Liquid cash & equivalents
Net Debt (Loans − Cash)
-
Net loan obligation
Debt to Equity & Interest Cover
-
Interest cover: 1.4x EBIT
Operating Cash Flow (OCF)
-
Cash generated from operations
Free Cash Flow (FCF)
-
OCF minus Capex
About VALIANT LABORATORIES
Market capRs 412 CrMicro cap · 4.35 Cr shares
First listed06 Oct 2023BSE not available · NSE 06 Oct 2023
Face valueRs 10
Book valueRs 54.51Price is 1.7x book value
ROE0.1%weak, below 8%
ROCE-0.2%losing money on capital
Profile completeness6 of 8Missing: description, industry · ratios as of FY2024
Shareholding
Promoters and group 74.94% 0.00 pp, public 25.06%, as on 30 Sep 2026. Holder names and history
Day range94.91 to 94.91Open 94.91
52-week high141.38
-32.9% from high (19 Oct 2026)
52-week low49.51
+91.7% from low (04 Mar 2026)
Volume18,314
1.0x the 20-day average
RSI (14)23
oversold
Volatility (30d)40.8%annualised
Returns
1W-9.6%
1M-29.0%
3M-0.9%
6M+23.5%
1Y+23.3%
YTD+35.6%
3Y a year-19.9%
Against the NIFTY 50
| Period | VALIANTLAB | NIFTY 50 | Difference |
|---|---|---|---|
| 1M | -29.0% | +13.1% | -42.1 pts |
| 3M | -0.9% | +6.4% | -7.3 pts |
| 6M | +23.5% | +8.8% | +14.7 pts |
| 1Y | +23.3% | -1.5% | +24.8 pts |
Risk over the past year
Volatility53%high
Deepest fall-33.9%from a peak
Beta0.64moves less than the index
Best day+14.2%09 Feb 2026
Worst day-7.7%23 Mar 2026
Up days44%of sessions
🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition
Piotroski F-Score: 1 / 9 · Weak / Watch Balance Sheet
⚠ Positive Net Profit (PAT > 0)
Rs -3.28 Cr
⚠ Positive Operating Cash Flow (OCF > 0)
N/A
⚠ High Cash Conversion (OCF >= 85% of PAT)
N/A
⚠ Improving Return on Assets (ROA YoY)
N/A
⚠ Conservative / Decreasing Debt-to-Equity
Bank/Low
⚠ Healthy Balance Sheet Asset Coverage
Verified
⚠ Institutional Return on Equity (ROE >= 14%)
N/A
✓ Stable / Expanding Profit Margin YoY
-1.4% vs -3.5%
⚠ Asset Turnover Efficiency (Sales / Assets)
N/A
Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration)
| Rs crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales / Revenue | 35.2 | 57.8 | 46.8 | 46.2 | 52.5 | 92.0 | 115 | 117 |
| Sales QoQ % | +64.0% | +64.0% | -19.0% | -1.3% | +13.5% | +75.3% | +25.3% | +1.3% |
| Operating Profit | 0.62 | 3.82 | 2.39 | 0.08 | -0.89 | 4.81 | 29.3 | 5.18 |
| Operating Margin (OPM %) | 1.8% | 6.6% | 5.1% | 0.2% | -1.7% | 5.2% | 25.4% | 4.4% |
| Net Profit (PAT) | 1.60 | 0.70 | 1.82 | 0.20 | -7.06 | 1.76 | 21.1 | 0.41 |
| Profit QoQ % | +126.8% | -56.3% | +160.0% | -89.0% | -3630.0% | +124.9% | +1098.9% | -98.1% |
| Profit YoY % | +145.7% | +157.4% | +280.2% | +103.3% | -541.3% | +151.4% | +1059.3% | +105.0% |
| Net Margin % | 4.5% | 1.2% | 3.9% | 0.4% | -13.5% | 1.9% | 18.3% | 0.4% |
Sales and profit
Sales growth+14.2%a year, 2Y
Profit growth-a year, 2Y
EPS growth-a year, 2Y
Avg ROE-0.9%2 years
Profit and loss
| Rs crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales | 182 | 133 | 237 |
| Sales growth | - | -26.7% | +78.0% |
| Operating profit | -8.40 | -4.68 | 6.39 |
| Operating margin | -4.6% | -3.5% | 2.7% |
| Other income | 9.68 | 2.46 | 2.33 |
| Interest | 0.08 | 0.17 | 1.90 |
| Depreciation | 1.97 | 2.04 | 6.04 |
| Profit before tax | -0.77 | -4.43 | 0.78 |
| Tax rate | - | - | -523.1% |
| Net profit | 0.32 | -4.69 | -3.28 |
| Profit growth | - | -1565.6% | - |
| Net margin | 0.2% | -3.5% | -1.4% |
| EPS (Rs) | 0.13 | -1.10 | -0.55 |
Balance sheet
| Rs crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Equity (net worth) | 237 | - | - |
| Borrowings | 76.1 | - | - |
| Cash | 106 | - | - |
| Total assets | 343 | - | - |
| Debt to equity | 0.32x | - | - |
Debt, Loans, Cash Flow & Working Capital
| Rs crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Operating Cash Flow (OCF) | 1.89 | - | - |
| Capital Expenditure (Capex) | 45.9 | - | - |
| Free Cash Flow (FCF = OCF - Capex) | -44.0 | - | - |
| OCF / Net Profit Conversion | 5.91x | - | - |
| Total Borrowings / Loans | 76.1 | - | - |
| Cash & Bank Balances | 106 | - | - |
| Trade Receivables (Cr) | 45.7 | - | - |
| Receivable Days | 91.68x | - | - |
| Inventories (Cr) | 10.0 | - | - |
| Inventory Days | 20.09x | - | - |
Returns on capital
| Rs crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| ROE | 0.1% | -2.0% | - |
| ROCE | -0.2% | -1.4% | - |
| Interest cover | -8.63x | -25.06x | 1.41x |
Compared with its sector Pharma & Healthcare
| Stock | Price | Day | 1 year | Mkt cap (Cr) | P/E | P/B | ROE | Net margin |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMASUN PHARMACEUTICAL IND L | 1,884.90 | -0.8% | - | 452,244 | 39.4 | - | 15.0% | 19.7% |
| TORNTPHARMTORRENT PHARMACEUTICALS L | 4,689.50 | +1.7% | - | 158,505 | 74.2 | - | 24.2% | 15.3% |
| LAURUSLABSLAURUS LABS LIMITED | 2,294.60 | -0.5% | - | 123,667 | 139.4 | 23.3 | 16.8% | 13.1% |
| ZYDUSLIFEZYDUS LIFESCIENCES LTD | 1,200.00 | -0.2% | - | 120,720 | 24.0 | 4.5 | 18.9% | 18.9% |
| MANKINDMANKIND PHARMA LIMITED | 2,665.00 | +1.4% | - | 106,757 | 55.8 | 11.4 | 20.4% | 18.5% |
| MAXHEALTHMAX HEALTHCARE INS LTD | 1,081.00 | +3.9% | - | 105,063 | 72.9 | 9.8 | 13.4% | 17.2% |
| LUPINLUPIN LIMITED | 2,014.00 | +0.8% | - | 91,778 | 17.3 | - | 13.4% | 19.2% |
| GLENMARKGLENMARK PHARMACEUTICALS | 2,648.00 | +1.5% | - | 74,724 | - | 9.5 | -19.1% | -12.7% |
| FORTISFORTIS HEALTHCARE LTD | 825.00 | +1.9% | - | 62,284 | 59.8 | - | 7.8% | 11.7% |
| GLANDGLAND PHARMA LIMITED | 3,331.90 | +1.2% | - | 54,880 | 53.4 | - | 8.9% | 16.0% |
| IPCALABIPCA LABORATORIES LTD | 1,843.80 | -0.9% | - | 46,777 | 41.0 | 5.8 | 14.7% | 12.3% |
| GLAXOGLAXOSMITHKLINE PHARMA LT | 2,727.60 | +0.5% | - | 46,208 | 78.3 | 26.0 | 33.2% | 17.1% |
| Sector median | - | 55.8 | 6.7 | 13.6% |
Today: 15 minute chart and signal
Analysis and next-session reading
Signals
Price is below its 50-day average
20-day average is below the 50-day (short-term downtrend)
Price is above its 200-day average (long-term uptrend)
RSI 23: oversold zone, a bounce is more likely
When is a good price?
The price is in the lower half of its 1-year range and is lower than it was on 24% of days in the past year.
Support (prices below today's)
| 60-day low | 91.53 | -3.6% |
| 200-day average | 81.86 | -13.7% |
| 52-week low | 49.51 | -47.8% |
Resistance (prices above today's)
| 50-day average | 120.41 | +26.9% |
| 20-day high | 130.88 | +37.9% |
| 60-day high | 141.38 | +49.0% |
| 52-week high | 141.38 | +49.0% |
Zones buyers often watch
| Lower quarter of the 1-year range | 49.51 to 72.48 | Historically the cheapest part of the past year. |
| Pullback of 10% to 20% from the high | 113.10 to 127.24 | A common area for dips inside an uptrend. |
| Around the 200-day average | 79.40 to 84.32 | Long-term trend line, often watched as support. |
Moving averages and momentum
| Indicator | Value | Reading |
|---|---|---|
| 20-day average | 114.60 | Price is 17.2% below |
| 50-day average | 120.41 | Price is 21.2% below |
| 200-day average | 81.86 | Price is 15.9% above |
| RSI (14) | 23 | Oversold zone |
| MACD (12, 26, 9) | -6.71 | Below its signal line (momentum fading) |
| Volatility (30d) | 40.8% | Medium yearly swings |
Support and resistance
R294.91
R194.91
Pivot94.91
S194.91
S294.91
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| 2026-11-20 | 94.91 | 94.91 | 94.91 | 94.91 | -1.99% | 18,314 |
| 2026-11-19 | 96.84 | 96.84 | 96.84 | 96.84 | -1.99% | 3,348 |
| 2026-11-18 | 98.81 | 98.81 | 98.81 | 98.81 | -1.99% | 4,150 |
| 2026-11-17 | 100.82 | 100.82 | 100.82 | 100.82 | -1.99% | 2,203 |
| 2026-11-16 | 102.87 | 102.87 | 102.87 | 102.87 | -1.99% | 5,561 |
| 2026-11-13 | 104.96 | 104.96 | 104.96 | 104.96 | -2.00% | 2,665 |
| 2026-11-12 | 107.10 | 107.10 | 107.10 | 107.10 | -1.99% | 3,116 |
| 2026-11-11 | 109.28 | 109.28 | 109.28 | 109.28 | -2.00% | 3,590 |
| 2026-11-09 | 111.51 | 111.51 | 111.51 | 111.51 | -2.00% | 4,545 |
| 2026-11-06 | 116.10 | 116.10 | 116.10 | 116.10 | -1.99% | 3,573 |
| 2026-11-05 | 118.46 | 118.46 | 118.46 | 118.46 | -1.99% | 5,041 |
| 2026-11-04 | 120.87 | 120.87 | 120.87 | 120.87 | -1.99% | 10,754 |
| 2026-11-03 | 123.33 | 123.33 | 123.33 | 123.33 | -1.99% | 9,901 |
| 2026-11-02 | 125.85 | 128.60 | 125.84 | 125.84 | -1.99% | 77,172 |
| 2026-10-30 | 130.88 | 130.88 | 128.33 | 128.40 | +0.05% | 11,688 |
| 2026-10-29 | 125.00 | 128.33 | 125.00 | 128.33 | +1.99% | 37,932 |
| 2026-10-28 | 120.91 | 125.82 | 120.90 | 125.82 | +1.99% | 86,797 |
| 2026-10-27 | 123.36 | 123.36 | 123.36 | 123.36 | -1.99% | 6,312 |
| 2026-10-26 | 125.87 | 125.87 | 125.87 | 125.87 | -1.99% | 58,282 |
| 2026-10-23 | 128.43 | 128.43 | 128.43 | 128.43 | -2.00% | 9,957 |
| 2026-10-22 | 131.05 | 131.05 | 131.05 | 131.05 | -2.00% | 11,514 |
| 2026-10-21 | 138.40 | 138.40 | 133.72 | 133.72 | -4.99% | 106,424 |